Emerging Data and Treatment Trends in Paroxysmal Nocturnal Hemoglobinuria After EHA 2025 - Episode 5

Factors for Selecting Iptacopan in C5 Inhibitor–Naive and –Exposed PNH

July 23, 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, David Dingli, MD, PhD

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, detail factors for selecting iptacopan in C5 inhibitor–naive and –exposed PNH.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Reviewing Current Standards in Paroxysmal Nocturnal Hemoglobinuria

EP. 2: Role of C5 Inhibitors in the Management of Paroxysmal Nocturnal Hemoglobinuria

EP. 3: Implications of the FDA Approval of Iptacopan for PNH

EP. 4: Data for Iptacopan in PNH After Switching Anti-C5 Therapy: The APPULSE-PNH Trial

Now Viewing

EP. 5: Factors for Selecting Iptacopan in C5 Inhibitor–Naive and –Exposed PNH

EP. 6: Implications of APPULSE-PNH Data for Iptacopan in PNH

EP. 7: Addressing Further Unmet Needs in PNH